LLC «AG «Aspect» (Veterinarian)
LLC «RDE «Astrapharm» (Leading veterinarian)
LLC «BioFeron» (Leading veterinarian)
employee
Russian Federation
employee
Russian Federation
LLC AG Aspect (Scientific consultant)
LLC «RDE «Astrapharm» (Scientific consultant)
Russian Federation
LLC «RDE «Astrapharm» (Chief science specialist)
LLC «BioFeron» (Chief science specialist)
employee
Russian Federation
CSCSTI 68.41
This study evaluated the safety and tolerance of the anthelmintic drug Supramil® emulsion in pregnant and lactating queens. The formulation represents a novel liquid preparation containing a combination of R-praziquantel (levorotatory optical isomer) and milbemycin oxime. Unlike products containing racemic praziquantel, the use of the active enantiomer enables a 50 % reduction in cestocidal dose while improving the safety profile to hazard class IV (practically non-toxic) according to GOST 12.1.007-76. The objective was to assess tolerance of the drug at a triple therapeutic dose (7.5 mg/kg R-praziquantel and 6.0 mg/kg milbemycin oxime, equivalent to 1.5 mL/kg) administered orally once weekly throughout 9 weeks of gestation and 8 weeks of lactation. Twelve healthy non-breed queens (age 18…24 months, body weight 3.5…3.9 kg) were randomly allocated to treatment (n=6) or control (n=6) groups. Following quarantine, vaccination, and ectoparasite treatment at a boarding facility, queens were bred with three proven healthy toms; pregnancy was confirmed by ultrasonography at 21±3 days after cessation of estrous behavior. The treatment group received Supramil® emulsion weekly during gestation and lactation; controls received vehicle without active ingredients. Clinical parameters, body weight, hematological and biochemical profiles, adverse events, parturition, and kitten development (n=43) were monitored. Result showed no clinically and statistically significant differences between groups in behavior, appetite, body weight, hemoglobin, erythrocyte counts, leukograms, or biochemical markers (p>0.05). No adverse events occurred. Gestation length (mean 61–62 days), parturition (uncomplicated), and reproductive parameters (3.5…3.67 live kittens per litter, zero mortality) were comparable (p=0.619; 0.575). Kittens (age 2…56 days) exhibited normal neurological, musculoskeletal, and growth development. These findings confirm that Supramil® emulsion at the recommended single-dose regimen is safe for use in pregnant and lactating queens, demonstrating excellent tolerance even with repeated administration at a triple therapeutic dose.
Supramil® emulsion, R-praziquantel, milbemycin oxime, queens, intact female cats, kittens, pregnancy, lactation, safety, tolerability, hematology, biochemistry, blood
1. Arhipov, I.A. Antigel'mintiki: farmakologiya i primenenie / I.A. Arhipov. ‒ M.: 2009 – S. 263-265.
2. GOST R 58090-2018. «Nacional'nyy standart Rossiyskoy Federacii. Klinicheskoe obsledovanie neproduktivnyh zhivotnyh. Obschie trebovaniya» (utv. i vveden v deystvie Prikazom Rosstandarta ot 22.03.2018 № 143-st).
3. Instrukciya po veterinarnomu primeneniyu lekarstvennogo preparata Supramil® tabletki [Elektronnyy resurs]. – URL: https://galen.vetrf.ru/files/2619c020-5716-4037-a824-0ab4ae02b172 (data obrascheniya 30.09.2025).
4. Instrukciya po veterinarnomu primeneniyu lekarstvennogo preparata Milprazon tabletki dlya koshek [Elektronnyy resurs]. – URL: https://galen.vetrf.ru/files/f93781e9-9137-497f-8849-d991832cb48a (data obrascheniya 30.09.2025).
5. Instrukciya po veterinarnomu primeneniyu lekarstvennogo preparata Mil'bemaks tabletki dlya koshek [Elektronnyy resurs]. – URL: https://galen.vetrf.ru/files/72a36c8e-5040-43b7-add7-7e94998844b9 (data obrascheniya 30.09.2025).
6. Mukaseev, S.V. Ocenka perenosimosti antigel'mintnogo preparata Supramil® tabletki sobakami i koshkami / Mukaseev S.V., Zeynalov O.A. // Rossiyskiy veterinarnyy zhurnal. ‒ 2023. ‒ № 3-4. ‒ S. 15-25.
7. Mukaseev, S.V. Ocenka perenosimosti lekarstvennogo preparata Supramil® emul'siya sobakami i koshkami / S.V. Mukaseev, S.A. Parhomenko, D.V. Beloglazov, O.A. Zeynalov // Veterinariya i kormlenie. – 2025. ‒ №4 – S. 71-79.
8. Orobec, V.A. Doklinicheskaya ocenka bezopasnosti novogo lekarstvennogo preparata dlya sobak i koshek Supramil® emul'siya / V.A. Orobec, O.I. Sevost'yanova, E.S. Kastarnova, S.V. Mukaseev. O.A. Zeynalov // Rossiyskiy veterinarnyy zhurnal. ‒2024. ‒№3. ‒ S. 13-26.
9. Orobec, V.A. Ocenka terapevticheskoy effektivnosti suspenzii Prazitel® Osobyy pri kishechnyh gel'mintozah schenkov i kotyat / V.A. Orobec, O.I. Sevost'yanova, I.V. Zaichenko, S V. Mukaseev // Rossiyskiy veterinarnyy zhurnal. ‒ 2019. ‒ № 7. ‒ S. 25-32.
10. Orobec, V.A. Toksikologicheskaya ocenka antigel'mintnogo preparata Supramil® tabletki dlya sobak i koshek / V.A. Orobec, S.V. Mukaseev. O.A. Zeynalov // Veterinariya. ‒ 2022. ‒ №6. ‒ S. 55-62.
11. Orobec, V.A. Effektivnost' novogo antigel'mintnogo preparata Supramil® tabletki pri kishechnyh gel'mintozah sobak i koshek / V.A. Orobec, O.I. Sevost'yanova, I.V. Zaichenko, S.V. Mukaseev, O.A. Zeynalov // Rossiyskiy veterinarnyy zhurnal. ‒ 2022. ‒ № 1. ‒ S. 30-41. DOI:https://doi.org/10.32416/2500-4379-2022-2-30-41.
12. Orobec, V.A. Effektivnost' novogo antigel'mintnogo preparata Prazitel® Osobyy pri lechenii kishechnyh gel'mintozov sobak starshe 6 let/ V.A. Orobec, O.I. Sevost'yanova, I.V. Zaichenko, S.V. Mukaseev // Rossiyskiy veterinarnyy zhurnal. ‒ 2018. ‒ № 2. ‒ S. 45-48.
13. Ostraya peroral'naya toksichnost' substancii R-prazikvantela (organizaciya-razrabotchik OOO «NVP «Astrafarm», Rossiya) na laboratornyh zhivotnyh. Otchet o NIR. OOO «MNIC «OZOS», 2015. ‒ 12 s.
14. Shinkarenko, A.N. Ocenka effektivnosti novogo antigel'mintnogo preparata Supramil® tabletki dlya profilaktiki dirofilyarioza sobak / A. N. Shinkarenko, K. S. Kamenov, S. V. Mukaseev, O. A. Zeynalov // Rossiyskiy veterinarnyy zhurnal. ‒ 2022. ‒ № 3-4. ‒ S. 31-35. DOI:https://doi.org/10.32416/2500-4379-2022-3-4-31-35.
15. Dollery, C.T. Praziquantel. In: Therapeutic Drugs, vol. 2, second ed. Churchill Livingstone, Edinburgh, 1999. ‒ pp. 184-188.
16. EMEA. European Medicines Evaluation Agency. Praziquantel. Summary Report by CVMP. EMEA/MRL/141/96. EMEA, 1996, London.
17. Frohberg, H. Results of toxicological studies on praziquantel / H. Frohberg // Arzneim-Forsch/Drug Res. ‒ 1984. ‒ No. 34. ‒ pp. 1137-1144.
18. Ide, J. Milbemycin: discovery and development / J. Ide, T. Okazaki, M. Ono, A. Saito, K. Nakagawa, S. Naito, K. Sato, K. Tanaka, H. Yoshikawa, M. Ando, S. Katsumi, K. Matsumoto, T. Toyama, M. Shibano, M. Abe // Annual Report Sankyo Research Laboratories (Sankyo Kenkyusho Nenpo). ‒ 1993. ‒ No. 45. ‒ pp, 1-98.
19. Olliaro, P. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer) / P. Olliaro, P. Delgado-Romero, J. Keiser // J. Antimicrob. Chemother. ‒ 2014. ‒ No. 69 (4). ‒ rr. 863-870.
20. Papich, M.G. Pharmacological considerations during pregnancy in small animals / M.G. Papich // Proc. Soc. Therio, Annu Meeting (Ontario), 1990, p. 224.
21. Plumb, D.C. Veterinary drug handbook / D.C. Plumb. ‒ Ames, Iowa: Blackwell Publishing, 2008. ‒ 1136 p.
22. Schenker, R. Repeat dose tolerance of a combination of milbemycin oxime and praziquantel in breeding and lactating queens / R. Schenker, R. Cody, G. Strehlau, P. Junquera // International Journal of Applied Research in Veterinary Medicine. ‒ 2005. ‒ No. 3. ‒ pp. 360-366.
23. Vercruysse, J. Macrocyclic lactones in antiparasitic therapy / J. Vercruysse, R.S. Rew, ‒ New York: CABI Publishing, 2002. ‒ 464 p.
